USPTO serial 79276391
SIMCERE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 24, 2020
- Examiner
- VO, JULIE
- Law office
- TMO LAW OFFICE 123
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SIMCERE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jiangsu Simcere Pharmaceutical Co., Ltd
CN
Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
Jiangsu Simcere Pharmaceutical Co., Ltd
CN
Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
Jiangsu Simcere Pharmaceutical Co., Ltd
CN
Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dana Stewart-Mekdara
Dana Stewart-Mekdara Global Trademarks, Inc.505 S. Villa Real Drive, Suite 102Anaheim Hills, CA 92807UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicated troches; Medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; [ Biochemicial ] * Biochemical * drug for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musculo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical purposes; Active pharmaceutical ingredients, namely, extracts of hops for pharmaceutical purposes, eucalyptus for pharmaceutical purposes, mint for pharmaceutical purposes, malt for pharmaceutical purposes, pepsins for pharmaceutical purposes,thymol for pharmaceutical purposes,turpentine for pharmaceutical purposes, flaxseed for pharmaceutical purposes, ferments for pharmaceutical purposes, cytostatics for pharmaceutical purposes, balms for pharmaceutical purposes, digestives for pharmaceutical purposes, iodine for pharmaceutical purposes, alcohol for pharmaceutical purposes, starch for pharmaceutical purposes; Pharmaceutical preparations for injection for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chinese patent medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, and, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
- Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
- Other trademarks owned by Jiangsu Simcere Pharmaceutical Co., Ltd
- Other trademarks in Class 005
- Similar marks named SIMCERE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 24, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 18, 2024 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Apr 8, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 12, 2023 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Aug 16, 2023 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Aug 8, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 8, 2023 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Aug 8, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 9, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Oct 27, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 21, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 26, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 26, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 24, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 24, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 8, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 8, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 3, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 3, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 3, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 3, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 3, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 27, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 27, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 27, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 24, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 23, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 23, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 22, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 22, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 28, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 27, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 17, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 16, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |